论文部分内容阅读
目的对比华法林和阿司匹林预防房颤患者卒中的疗效。方法将85例房颤患者随机分成华法林组43例和阿司匹林组42例。分别采用华法林和阿司匹林进行抗凝治疗,疗程1年。比较治疗前后2组患者的凝血指标变化及用药后并发症情况,记录终点事件。结果治疗前2组患者PT、APTT、INR、FIB水平比较差异无统计学意义(P>0.05);治疗后2组PT、APTT、INR水平均高于治疗前,且华法林组高于阿司匹林组(P<0.05)。治疗后2组FIB水平均升高(P<0.05),但2组间比较差异无统计学意义(P>0.05)。华法林组不良终点事件的发生率为4.65%(2/43)显著低于阿司匹林组的21.43%(9/42),差异有统计学意义(P<0.05)。华法林组出血率为16.28%(7/43)与阿司匹林组的9.52%(4/42)对比差异无统计学意义(P>0.520)。结论应用华法林对房颤患者进行抗凝治疗,有效性和安全性较高,减少不良结局风险,可临床参考。
Objective To compare the efficacy of warfarin and aspirin in the prevention of stroke in patients with atrial fibrillation. Methods A total of 85 patients with atrial fibrillation were randomly divided into warfarin group (43 cases) and aspirin group (42 cases). Respectively warfarin and aspirin for anticoagulant therapy, treatment for 1 year. The changes of coagulation index and the complication after treatment were compared between two groups before and after treatment, and the end point events were recorded. Results The levels of PT, APTT, INR and FIB in the two groups before treatment were not significantly different (P> 0.05). The levels of PT, APTT and INR in the two groups after treatment were higher than before treatment, and were higher in warfarin group than in aspirin Group (P <0.05). After treatment, FIB levels in both groups increased (P <0.05), but there was no significant difference between the two groups (P> 0.05). The incidence of adverse endpoint in warfarin group was 4.65% (2/43), which was significantly lower than that in aspirin group (21.43%, 9/42) (P <0.05). Bleeding rate was 16.28% (7/43) in warfarin group and 9.52% (4/42) in aspirin group. There was no significant difference (P> 0.520). Conclusion Warfarin in patients with atrial fibrillation anticoagulant therapy, effective and safe, reduce the risk of adverse outcomes, clinical reference.